Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 10.2 percent. This is a 40.54 percent increase over losses of $(0.37) per share from the same period last year. The company reported $212.000 thousand in sales this quarter. This is a 29.10 percent decrease over sales of $299.000 thousand the same period last year.